Kunihiro Suzuki

2.2k total citations · 1 hit paper
57 papers, 1.6k citations indexed

About

Kunihiro Suzuki is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Kunihiro Suzuki has authored 57 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 19 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Surgery. Recurrent topics in Kunihiro Suzuki's work include Diabetes Treatment and Management (12 papers), dental development and anomalies (9 papers) and Diabetes Management and Research (7 papers). Kunihiro Suzuki is often cited by papers focused on Diabetes Treatment and Management (12 papers), dental development and anomalies (9 papers) and Diabetes Management and Research (7 papers). Kunihiro Suzuki collaborates with scholars based in Japan, United States and South Korea. Kunihiro Suzuki's co-authors include Yoshimasa Aso, Teruo Jojima, Toshie Iijima, Kazumi Akimoto, Chie Aoki, Kanako Kato, Masaaki Sagara, Masanori Shimizu, Hideyuki Hiraishi and Hidehiro Takekawa and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Development and Diabetes.

In The Last Decade

Kunihiro Suzuki

56 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

2018 286 citations Masanori Shimizu, Kunihiro Suzuki et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Kunihiro Suzuki	679	507	433	357	267	57	1.6k
Birgit Knebel	353 0.5×	838 1.7×	502 1.2×	339 0.9×	152 0.6×	84	1.7k
Narihito Yoshioka	685 1.0×	625 1.2×	273 0.6×	415 1.2×	133 0.5×	44	1.8k
Joseph L. Messina	491 0.7×	1.0k 2.0×	241 0.6×	279 0.8×	121 0.5×	76	1.8k
Rachel C. Janssen	289 0.4×	869 1.7×	595 1.4×	387 1.1×	121 0.5×	55	2.1k
T. Toyota	292 0.4×	490 1.0×	407 0.9×	727 2.0×	85 0.3×	64	2.2k
José O. Alemán	315 0.5×	572 1.1×	368 0.8×	296 0.8×	68 0.3×	46	1.4k
Antonio Martín‐Duce	211 0.3×	552 1.1×	410 0.9×	236 0.7×	122 0.5×	29	1.3k
Daniel Giannella‐Neto	736 1.1×	526 1.0×	394 0.9×	397 1.1×	36 0.1×	71	1.8k
Xuelian Xiong	221 0.3×	708 1.4×	646 1.5×	205 0.6×	64 0.2×	34	1.5k
Mikkel Holm Vendelbo	426 0.6×	969 1.9×	344 0.8×	299 0.8×	98 0.4×	93	2.5k

Countries citing papers authored by Kunihiro Suzuki

Since Specialization

Citations

This map shows the geographic impact of Kunihiro Suzuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunihiro Suzuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunihiro Suzuki more than expected).

Fields of papers citing papers by Kunihiro Suzuki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kunihiro Suzuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunihiro Suzuki. The network helps show where Kunihiro Suzuki may publish in the future.

Co-authorship network of co-authors of Kunihiro Suzuki

This figure shows the co-authorship network connecting the top 25 collaborators of Kunihiro Suzuki. A scholar is included among the top collaborators of Kunihiro Suzuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kunihiro Suzuki. Kunihiro Suzuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wakamatsu, Yoshio & Kunihiro Suzuki. (2019). Sequence alteration in the enhancer contributes to the heterochronic Sox9 expression in marsupial cranial neural crest. Developmental Biology. 456(1). 31–39. 6 indexed citations

Wakamatsu, Yoshio, et al.. (2019). Homeobox code model of heterodont tooth in mammals revised. Scientific Reports. 9(1). 12865–12865. 9 indexed citations

Suzuki, Kunihiro, Chie Aoki, Kanako Kato, et al.. (2017). Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study. Diabetes Therapy. 8(2). 445–449. 1 indexed citations

Jojima, Teruo, Kohsuke Uchida, Kazumi Akimoto, et al.. (2017). Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis. 261. 44–51. 91 indexed citations

Yamaguchi, Masaru, et al.. (2017). Relationship between root resorption and individual variation in the calcium/phosphorous ratio of cementum. American Journal of Orthodontics and Dentofacial Orthopedics. 152(4). 465–470. 7 indexed citations

Aso, Yoshimasa, Kunihiro Suzuki, Minoru Sato, et al.. (2017). Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I’D GOT trial. Diabetes Research and Clinical Practice. 130. 237–243. 22 indexed citations

Matsumura, Mihoko, Yuki Nakatani, Chie Aoki, et al.. (2017). Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM). Diabetes Therapy. 8(4). 821–827. 37 indexed citations

Iijima, Toshie, et al.. (2017). Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells. Diabetes Research and Clinical Practice. 133. 10–12. 14 indexed citations

Jojima, Teruo, et al.. (2016). Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetology & Metabolic Syndrome. 8(1). 45–45. 166 indexed citations

10.

Aso, Yoshimasa, Masaaki Sagara, Teruo Jojima, et al.. (2015). Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Research and Clinical Practice. 110(3). 250–256. 34 indexed citations

11.

Aso, Yoshimasa, Teruo Jojima, Toshie Iijima, et al.. (2015). Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes. Endocrine. 50(3). 659–664. 28 indexed citations

12.

Suzuki, Kunihiro, Seiichi Tanaka, Chie Aoki, et al.. (2014). Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin. 41(3). 211–220. 8 indexed citations

13.

Wakamatsu, Yoshio, Tadashi Nomura, Noriko Osumi, & Kunihiro Suzuki. (2014). Comparative gene expression analyses reveal heterochrony for Sox9 expression in the cranial neural crest during marsupial development. Evolution & Development. 16(4). 197–206. 19 indexed citations

14.

Tanaka, Seiichi, et al.. (2014). Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy. Diabetes Technology & Therapeutics. 16(12). 840–845. 23 indexed citations

15.

Suzuki, Kunihiro, et al.. (2013). Hyperparathyroidism caused by a functional parathyroid cyst. BMJ Case Reports. 2013. bcr2012008290–bcr2012008290. 11 indexed citations

16.

Aso, Yoshimasa, Kanako Kato, Teruo Jojima, et al.. (2013). The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Translational research. 162(5). 309–316. 21 indexed citations

17.

Aoki, Chie, et al.. (2012). Miglitol, an Anti-diabetic Drug, Inhibits Oxidative Stress^|^ndash;Induced Apoptosis and Mitochondrial ROS Over-Production in Endothelial Cells by Enhancement of AMP-Activated Protein Kinase. Journal of Pharmacological Sciences. 120(2). 121–128. 17 indexed citations

18.

Suzuki, Kunihiro, Gábor Oláh, Katalin Módis, et al.. (2011). Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proceedings of the National Academy of Sciences. 108(33). 13829–13834. 250 indexed citations

19.

Suzuki, Kunihiro, et al.. (2010). An ACTH-secreting Pituitary Adenoma Within the Sphenoid Sinus. Internal Medicine. 49(8). 763–766. 1 indexed citations

20.

Suzuki, Kunihiro, Kosuke Doki, Masato Homma, et al.. (2008). Co‐administration of proton pump inhibitors delays elimination of plasma methotrexate in high‐dose methotrexate therapy. British Journal of Clinical Pharmacology. 67(1). 44–49. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact